Skip to main content
. 2022 Jan 7;2022:3123878. doi: 10.1155/2022/3123878

Table 1.

The details of the study characteristics.

No. Author year Experiment group size (EG) Control group size (CG) Age (median or mean and standard deviation) (year) Is the baseline consistent? Course of intervention (days) Intervention group Control group Primary outcome evaluation scales (QOL) Secondary outcomes
1 He X 2016 79 81 EG: 46.82 ± 7.19 Yes 21 d; 9 periods AF (ADM+5-FU)/AC (ATM + CTX) chemotherapy and radiotherapy and Chinese herbal medicine; A: 50 mg/m2, F: 500 mg/m2; A: 60 mg/m2, C: 600 mg/m2 Chinese herbal medicine 400 ml/d FACT-B 1, 5, 9 11
CG: 47.17 ± 8.28
2 Yu F 2019 46 47 EG: 52.40 ± 10.50 Yes 21 d; 6 periods AD (D: docetaxel) chemotherapy and Xiaoaiping; A: 50 mg/m2, D: 75 mg/m2 Xiaoaiping 7.2 g/d FACT-B 1, 5, 9
CG: 51.50 ± 8.60
3 Diao H 2018 47 47 EG: 51.68 ± 9.36 Yes 21 d; 6 periods CEF (E: epirubicin) chemotherapy and Shenqi Fuzheng injection; C: 500 mg/m2, E: 100 mg/m2, F: 500 mg/m2 Shenqi Fuzheng injection 250 ml/d QLQ-BR53 1, 3
CG: 52.94 ± 10.14
4 Li L 2015 30 30 EG: 51.64 ± 10.29 Yes 21 d; 4 periods TAC (T: TAX) chemotherapy and self-made Chinese herbal medicine; T: 75 mg/m2, A: 50 mg/m2, C: 500 mg/m2 Self-made Chinese herbal medicine KPS 5
CG: 49.66 ± 8.58
5 Liu L 2009 20 20 EG: 61.45 ± 5.24 Yes 28 d; 2 periods TP (P: DDP) chemotherapy and replenishing Qi and nourishing Yin recipe; T: 60 mg/m2, P: 60–100 mg/m2 Replenishing Qi and nourishing Yin recipe 200 ml/d KPS 6, 7, 8
CG: 61.05 ± 4.48
6 Tang H 2016 40 39 EG: 47.50 ± 6.90 Yes 21 d; 4 periods CEF chemotherapy and replenishing Qi and nourishing Yin recipe; C: 500 mg/m2 , E: 60 mg/m2, F: 500 mg/m2 Replenishing Qi and nourishing Yin recipe 150 ml/d QLQ-C30 1, 6, 8
CG: 48.10 ± 6.30
7 Wang F 2018 23 23 EG: 40.36 ± 1.28 Yes 21 d; 3 periods TP chemotherapy and self-made nourishing Yin recipe; T: 60 mg/m2, E: 75 mg/m2 Self-made nourishing Yin recipe 150 ml/d KPS 6
CG: 41.03 ± 1.18
8 Wu C 2018 63 63 EG: 44.02 ± 5.16 Yes 3 months Tamoxifen citrate 20 mg/d and cantharidin capsules Cantharidin capsules 1.5 g/d QOL-C3 3, 5
CG: 44.16 ± 5.19
9 Zhang Y 2016 52 52 EG: 52.70 ± 5.60 Yes 6 months Tamoxifen citrate 60 mg/d and Tiaoqi Deji Fang Tiaoqi Deji Fang 400 ml/d QLQ-BR53 2, 8
CG: 53.40 ± 5.10
10 Zhang Y 2010 18 18 EG: 57.63 ± 8.42 Yes 28 d; 2 periods TD chemotherapy and replenishing Qi and nourishing blood recipe; T: 60 mg/m2, D: 60–100 mg/m2 Replenishing Qi and nourishing blood recipe 300 ml/d FACT-B 5, 6, 7, 8, 10
CG: 56.69 ± 8.59
11 Zhou Y 2018 54 54 EG: 68.18 ± 3.62 Yes 6 months LENM (L: letrozole; E: exemestane; N: nolvadex; M: megestrol) chemotherapy and Yi Wenyang prescription; L: 2.5 mg/d, E: 25 mg/d, T: 20 mg/d, M: 160 mg/d Yi Wenyang prescription 400 ml/d QLQ-BR53 -
CG: 57.27 ± 10.76
12 Zhu L 2010 20 20 EG: 52.5 ± 8.91 Yes 21 d; 2 periods AT chemotherapy and self-made different power elimination formulas; A: 60 mg/m2, T: 175 mg/m2 Self-made different power elimination formulas 300 ml/d KPS 1, 5, 6, 9, 11
CG: 50.25 ± 12.58
13 Dong L 2017 30 30 EG: 51.68 ± 9.36 Yes 21 d; 3 periods CED chemotherapy and nourishing spleen and kidney recipe; D: 75 mg/m2, E: 50 mg/m2, C: 500 mg/m2 Nourishing spleen and kidney recipe 200 mg/d KPS 7, 8, 10
CG: 52.94 ± 10.14
14 Du Y 2015 30 30 EG: 30.00–69.00 Yes 28 d; 4 periods CDF chemotherapy and modified Xiaoyao San; C: 500 mg/m2 , D: 50 mg/m2 , F: 500 mg/m2 Modified Xiaoyao San KPS 8, 11
CG: 29.00–70.00
15 Li G 2015 52 52 EG: 58.5 ± 6.57 Yes 28 d; 6 periods Letrozole: 2.5 g/d & lychee saponins Lychee saponins 6 tips/d KPS 1, 2, 3, 5
CG: 57.8 ± 6.55
16 Lu M 2016 45 45 EG and CG: 30.00–60.00 Yes 21 d; 2 periods CEF chemotherapy and Huaier granules; C: 60 mg/m2 E: 100 mg/m2 F: 60 mg/m2 Huaier granules 60 g/d KPS 1, 3
17 Ren K 2013 32 32 EG and CG: 28.00–79.00 Yes 21 d; 6 periods CEF chemotherapy and Kanglaite soft capsule C: 500 mg/m2 E: 75 mg/m2 F: 500 mg/m2 Kanglaite soft capsule 10.8 g/d KPS 4, 9
18 Song X 2016 50 50 EG: 35.00–62.00 Yes 21 d; 4 periods ACT chemotherapy and Chaihu Shugan powder; A: 60 mg/m2, C: 600 mg/m2, T: 75 mg/m2 Chaihu Shugan powder 500 ml/d KPS 5, 7, 8, 10
CG: 36.00–65.00
19 Xu C 2016 40 40 EG: 49.31 ± 5.28 Yes 28 d; 6 periods ACF chemotherapy and nourishing Qi and spleen decoction; A: 60 mg/m2, C: 600 mg/m2, F: 500 mg/m2 Nourishing Qi and spleen soup 180 ml/d KPS 1, 5, 8
CG: 49.57 ± 6.35
20 Yin H 2014 20 20 EG: 55.56 ± 5.64 Yes 21 d; 3 periods CD chemotherapy and Ruyan Xiaoji Fang; C: 600 mg/m2, D: 75 mg/m2 Ruyan Xiaoji Fang KPS 1, 5, 6, 8
CG: 53.89 ± 5.67
21 Zhang A 2016 30 30 EG: 52.70 ± 11.40 Yes 21 d; 6 periods ACD chemotherapy and self-made Fuzheng negative soup; A: 50 mg/m2, C: 50 mg/m2, D: 50 mg/m2 Self-made Fuzheng negative soup KPS -
CG: 52.40 ± 10.20
22 Zhang Y 2011 23 22 EG: 51.24 ± 7.80 Yes 21 d; 2 periods CFP chemotherapy and Fuzheng Jiedu Quyu recipe; C: 500 mg/m2, F: 40 mg/m2, P: 400 mg/m2 Fuzheng Jiedu Quyu recipe 250 ml/d KPS 1, 3, 5, 6, 7
CG: 48.29 ± 7.26

Notes. 1. Intervention group: A = Adriamycin; C = cyclophosphamide; D = docetaxel; E = epirubicin; F = fluorouracil; L = letrozole; M = megestrol; P = paclitaxel; T = tamoxifen. 2. Secondary outcomes: 1. white blood cell (WBC), platelet, and natural killer (NK) cell counts; 2. hormone levels, including estrogen (E2) and follicle-stimulating hormone (FSH); 3. immune function markers; 4. body mass index (BMI); 5. incidence of adverse reactions (including gastrointestinal and cardiac dysfunction and their development related to cancer); 6. tumor markers; 7. safety and tolerance; 8. traditional Chinese medicine syndrome; 9. hair loss; 10. heart function; and 11. toxic side effect.